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Clinical Effectiveness of Beta-Blockers in Heart Failure
Findings From the OPTIMIZE-HF (Organized Program to Initiate
Lifesaving Treatment in Hospitalized Patients With Heart Failure) Registry
Adrian F. Hernandez, MD, MHS,*† Bradley G. Hammill, MS,*
Christopher M. O’Connor, MD, FACC,*† Kevin A. Schulman, MD,*† Lesley H. Curtis, PHD,*†
Gregg C. Fonarow, MD, FACC‡
Durham, North Carolina; and Los Angeles, California
Objectives We sought to examine associations between initiation of beta-blocker therapy and outcomes among elderly pa-
tients hospitalized for heart failure.
Background Beta-blockers are guideline-recommended therapy for heart failure, but their clinical effectiveness is not well
understood, especially in elderly patients.
Methods We merged Medicare claims data with OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hos-
pitalized Patients With Heart Failure) records to examine long-term outcomes of eligible patients newly initiated
on beta-blocker therapy. We used inverse probability–weighted Cox proportional hazards models to determine
the relationships among treatment and mortality, rehospitalization, and a combined mortality–rehospitalization
end point.
Results Observed 1-year mortality was 33%, and all-cause rehospitalization was 64%. Among 7,154 patients hospital-
ized with heart failure and eligible for beta-blockers, 3,421 (49%) were newly initiated on beta-blocker therapy.
Among patients with left ventricular systolic dysfunction (LVSD) (n  3,001), beta-blockers were associated with
adjusted hazard ratios of 0.77 (95% confidence interval [CI]: 0.68 to 0.87) for mortality, 0.89 (95% CI: 0.80 to
0.99) for rehospitalization, and 0.87 (95% CI: 0.79 to 0.96) for mortality–rehospitalization. Among patients with
preserved systolic function (n  4,153), beta-blockers were associated with adjusted hazard ratios of 0.94 (95%
CI: 0.84 to 1.07) for mortality, 0.98 (95% CI: 0.90 to 1.06) for rehospitalization, and 0.98 (95% CI: 0.91 to 1.06)
for mortality–rehospitalization.
Conclusions In elderly patients hospitalized with heart failure and LVSD, incident beta-blocker use was clinically effective and
independently associated with lower risks of death and rehospitalization. Patients with preserved systolic func-
tion had poor outcomes, and beta-blockers did not significantly influence the mortality and rehospitalization
risks for these patients. (J Am Coll Cardiol 2009;53:184–92) © 2009 by the American College of Cardiology
Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.09.031a
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geart failure is the most common discharge diagnosis for
edicare beneficiaries, and more than one-half of patients
dmitted for heart failure will be readmitted within 6
onths (1,2). Although outcomes for heart failure are poor,
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ccepted September 22, 2008.dvances in understanding of heart failure over the past 2
ecades have led to important advances in therapy. One
ajor advance is the clinical trial evidence for beta-blockers,
hich is now a cornerstone of heart failure treatment (3).
Among patients with heart failure and reduced systolic
unction who are enrolled in randomized clinical trials,
eta-blockers confer a 10% to 40% reduction in mortality
nd hospitalization within 1 year (4–6). Patients enrolled in
andomized clinical trials tend to be relatively young, have
elatively few comorbid conditions, and are not representa-
ive of the general heart failure population encountered in
linical practice (7). Moreover, patients’ care in clinical trials
ay be significantly better compared with that of the
eneral population of patients with heart failure. Thus,
here is limited data on the effectiveness and safety of
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January 13, 2009:184–92 Clinical Effectiveness of Beta-Blockerseta-blockers in non–clinical trial populations of patients
ith systolic dysfunction, and there are almost no data for
atients with preserved systolic function.
A number of studies have found that evidence-based
eart failure therapies are underused, especially in the
lderly (8–11). Although current guidelines recommend
hat populations underrepresented in heart failure clinical
rials—including elderly patients, women, racial/ethnic mi-
orities, and patients with comorbid conditions—should be
reated like the broader population in the absence of specific
vidence to the contrary, some physicians may be hesitant to
o so without additional evidence of effectiveness in these
opulations (3–6,12).
Given the limited evidence and the uncertainty, we
ought to measure the clinical effectiveness of beta-blockers
n a broad group of eligible elderly patients with heart failure
ho were newly initiated on beta-blocker therapy and
ischarged after a heart failure hospitalization.
ethods
ata sources. We merged data from the OPTIMIZE-HF
Organized Program to Initiate Lifesaving Treatment in Hos-
italized Patients With Heart Failure) registry and from
nrollment files and in-patient claims from the Centers for
edicare and Medicaid Services (CMS). OPTIMIZE-HF
as a national registry and performance-improvement pro-
ram for patients hospitalized with heart failure (13–16). This
ationwide patient registry was used to gather data on various
atient characteristics with a web-based information system.
n an approach similar to Joint Commission case ascertain-
ent of heart failure hospitalizations, eligibility for the
PTIMIZE-HF registry required patients to be adults hos-
italized for an episode of new or worsening heart failure as the
rimary cause of admission or with significant heart failure
ymptoms that developed during a hospital stay with a primary
ischarge diagnosis of heart failure. Similar to other national
ardiovascular registries and quality-reporting initiatives, data
egarding medical history, signs and symptoms, medications,
nd diagnostic tests were collected via a web-based registry.
he registry also includes data on contraindications, intoler-
nce, and other reasons for not prescribing therapy. All regions
f the U.S. are represented in the registry, and a variety of
nstitutions participated, from community hospitals to large
ertiary medical centers. The OPTIMIZE-HF protocol was
pproved by each participating center’s institutional review
oard or by a central institutional review board. Automated
lectronic data checks were used to prevent out-of-range
ntries and duplicate patients. A source data verification audit
f a random 5% of the first 10,000 records collected showed
etter than 99% concordance on 53% of the fields (118 of 223)
nd 95% concordance on 91% of the fields (205 of 223). Fields
ith less than 95% concordance were not used in this analysis.
The CMS files include all fee-for-service Medicare ben-
ficiaries age 65 years and older who were hospitalized with
diagnosis of heart failure (International Classification of diseases, Ninth Revision, Clini-
al Modification [ICD-9-CM]
28.x, 402.x1, 404.x1, 404.x3).
e matched patients in the
PTIMIZE-HF registry to
edicare enrollment and in-
atient data according to date of
irth, sex, admission date, dis-
harge date, and hospital site. Of
he 36,165 hospitalizations involv-
ng patients age 65 years and older,
e matched 29,301 (81%) to
MS claims, representing 25,901
nique patients. The OPTIMIZE-HF patients linked to
edicare claims had similar demographic characteristics and
utcomes as other Medicare beneficiaries hospitalized for heart
ailure (17). For example, compared with 925,161 non–
PTIMIZE-HF fee-for-service Medicare beneficiaries, the
PTIMIZE-HF patients were not different than non–
PTIMIZE-HF patients with respect to age (79.5 years vs.
9.8 years), sex (44.0% vs. 42.5% male), or race (89.1% vs.
8.6% nonblack).
The institutional review board of the Duke University
ealth System approved this study.
nalysis population. After exclusion of 1,212 patients
ho died before discharge, the merged dataset included
4,689 patients with heart failure age 65 years and older
ho were discharged alive from the hospital and for whom
edicare data were available (Fig. 1). For patients with
ultiple hospitalizations recorded in the registry, we used
nformation from the earliest hospitalization. We included
nly patients documented as eligible for beta-blocker ther-
py. We successively excluded patients who had docu-
ented contraindications or intolerance to beta-blockers
n  2,975), who were discharged or transferred to other
hort-term hospitals (n  309) or hospice (n  399), or
ho left against medical advice (n  49) (18). We also
xcluded patients who were missing information on admis-
ion beta-blocker status, discharge beta-blocker status, or
ischarge status (n  114) and patients with incomplete or
nconsistent Medicare follow-up history (n  364).
From the remaining patients, we created 2 analysis
ohorts. The first cohort—those with left ventricular sys-
olic dysfunction (LVSD)—included patients with either
ocumented left ventricular ejection fraction (LVEF) of
40% or qualitative documentation of LVSD (n  7,529).
he second cohort—those with preserved systolic func-
ion—included patients with either documented LVEF of
t least 40% or qualitative documentation of preserved
ystolic function (n 9,712). We excluded patients without
ocumentation of left ventricular function (n  3,238).
utcomes. The outcomes of interest were time to death,
ime to first rehospitalization, and time to death or first
ehospitalization within 1 year after hospital discharge. We
btained dates of death from the CMS enrollment files and
Abbreviations
and Acronyms
ACE  angiotensin-
converting enzyme
ARB  angiotensin
receptor blocker
CI  confidence interval
LVEF  left ventricular
ejection fraction
LVSD  left ventricular
systolic dysfunctionata regarding hospital admissions from the CMS in-
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Clinical Effectiveness of Beta-Blockers January 13, 2009:184–92atient files. We did not count subsequent admissions for
ehabilitation as rehospitalizations in this analysis.
rimary analyses. The primary analysis estimated the ef-
ect of newly initiated beta-blocker therapy versus no
eta-blocker therapy on mortality and all-cause rehospital-
zation at 1 year in eligible patients with heart failure who
ere naïve to beta-blockers at hospital admission. There
ere 3,001 patients in the LVSD cohort and 4,153 patients
n the preserved systolic function cohort. We analyzed the 2
ohorts separately. In sensitivity analyses, we replicated the
rimary analysis in all eligible patients regardless of whether
hey were taking beta-blockers before admission. That is,
e included both patients newly initiated on beta-blocker
herapy and those who were continuing beta-blocker ther-
py. We also explored whether findings for clinical effec-
iveness of beta-blockers differed between patients with
VEF of 40% to 49% compared with the overall cohort
ith preserved systolic function.
In the LVSD and preserved systolic function cohorts,
e also evaluated whether there was heterogeneity in the
ndings regarding beta-blocker effectiveness. Specifically,
Figure 1 Derivation of Analysis Populations Eligible for Beta-Blo
With Left Ventricular Systolic Dysfunction and Preserv
OPTIMIZE-HF  Organized Program to Initiate Lifesaving Treatment in Hospitalizede examined whether the effectiveness of beta-blockers aas the same for patients with and without chronic
bstructive pulmonary disease, renal insufficiency, and
iabetes mellitus.
tatistical analysis. We summarized baseline characteris-
ics by treatment group using percentages for categoric
ariables and medians and interquartile ranges for continu-
us variables. For comparisons by treatment group, we used
hi-square tests for categoric variables and Wilcoxon rank
um tests for continuous variables. We summarized ob-
erved mortality using a Kaplan-Meier estimator and rehos-
italization using the cumulative incidence function (19).
e estimated the unadjusted relationship between treat-
ent and outcome using a Cox proportional hazards model
n which treatment group was the only variable. We
stimated the adjusted relationship between treatment and
utcome using an inverse probability–weighted Cox propor-
ional hazards model (20,21). The weights in this model
ere based on propensity to receive treatment (Online
ppendix). Specifically, we used logistic regression models
o estimate the propensity to receive any beta-blocker at
ischarge (vs. no beta-blocker) as a function of age at
s
ystolic Function
ts With Heart Failure.cker
ed S
Patiendmission, sex, race, ischemic heart failure status, LVEF,
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January 13, 2009:184–92 Clinical Effectiveness of Beta-Blockersystolic blood pressure, smoking within the prior year, rales,
r lower-extremity edema at admission; serum sodium,
erum creatinine, and hemoglobin levels at admission; other
ischarge medications (i.e., angiotensin-converting enzyme
ACE] inhibitor or angiotensin receptor blocker [ARB]);
n-hospital procedures (i.e., angiography, mechanical venti-
ation, implantable cardioverter-defibrillator); and history of
iabetes mellitus, hyperlipidemia, atrial arrhythmia, chronic
bstructive pulmonary disease, reactive airway disease, ane-
ia, peripheral vascular disease, thyroid abnormality, prior
erebrovascular accident or transient ischemic attack, de-
ression, or renal insufficiency. To assess the heterogeneity
f effect by subgroup, we included treatment-by-subgroup
nteractions in separate inverse probability–weighted Cox
roportional hazards models. Because this approach resulted
aseline Characteristics of Eligible Patients With Heart Failure
Table 1 Baseline Characteristics of Eligible Patients With Hear
Left Ventricular Syst
Variable
Beta-Blockers
(n  1,800)
No B
(n
Age, median (IQR), yrs 78.0 (72.0–84.0) 80.0
Male sex 985 (54.7) 671
Race
African American 231 (12.8) 162 (
Asian/Pacific Islander 11 (0.6) 13 (
Caucasian 1,448 (80.4) 951 (
Native American 4 (0.2) 3 (
Other 62 (3.4) 38 (
Unknown 44 (2.4) 34 (
Hispanic ethnicity 60 (3.3) 38 (
Heart failure details
Ejection fraction
30% 1,145 (63.6) 700 (
30%–39% 655 (36.4) 501 (
40%–49% — —
50% — —
Ischemic etiology 883 (49.1) 632 (
Comorbid conditions and clinical characteristics
Diabetes mellitus 652 (36.2) 433 (
Hyperlipidemia 514 (28.6) 336 (
Atrial arrhythmia 542 (30.1) 403 (
Chronic obstructive pulmonary disease 451 (25.1) 326 (
Pulmonary reactive airway disease 64 (3.6) 38 (
Anemia 239 (13.3) 186 (
Peripheral vascular disease 258 (14.3) 174 (
Thyroid abnormality 248 (13.8) 217 (
Prior cerebrovascular accident or TIA 271 (15.1) 208 (
Depression 158 (8.8) 99 (
Smoker within the past year 240 (13.3) 134 (
Chronic renal insufficiency 244 (13.6) 213 (
Systolic blood pressure, median (IQR), mm Hg 117 (105.0–131.0) 118 (
Rales 1,172 (65.1) 761 (
Lower extremity edema 1,110 (61.7) 737 (
Serum sodium level 135 mmol/l 340 (18.9) 229 (
Serum creatinine level 2 mg/dl 1,503 (83.5) 929 (
Hemoglobin level 9 g/dl 58 (3.2) 52 (alues are expressed as n (%) unless otherwise indicated.
IQR  interquartile range; TIA  transient ischemic attack.n additional statistical comparisons, we required p  0.01
or the interactions to be considered statistically significant.
esults
n the primary analysis of the LVSD cohort (n  3,001),
hich included patients with heart failure and LVSD who
ere eligible for beta-blockers and naïve to beta-blockers at
dmission, 1,800 patients (60.0%) were newly initiated on
eta-blocker therapy. Table 1 shows the baseline character-
stics of the cohort by discharge beta-blocker status. Patients
ischarged on beta-blockers were slightly younger and had
ess atrial arrhythmia and renal insufficiency compared with
ligible patients discharged without beta-blockers.
lure
sfunction Preserved Systolic Function
ockers
01) p Value
Beta-Blockers
(n  1,621)
No Beta-Blockers
(n  2,532) p Value
85.0) 0.001 80.0 (74.0–86.0) 81.0 (75.0–87.0) 0.01
0.54 555 (34.2) 863 (34.1) 0.92
0.70 0.004
218 (13.4) 256 (10.1)
17 (1.0) 21 (0.8)
1,297 (80.0) 2,097 (82.8)
6 (0.4) 5 (0.2)
42 (2.6) 57 (2.3)
41 (2.5) 96 (3.8)
0.80 43 (2.7) 64 (2.5) 0.80
0.003 0.001
— —
— —
653 (40.3) 872 (34.4)
968 (59.7) 1,660 (65.6)
0.06 559 (34.5) 752 (29.7) 0.001
0.93 597 (36.8) 924 (36.5) 0.83
0.73 446 (27.5) 657 (25.9) 0.27
0.05 532 (32.8) 930 (36.7) 0.01
0.20 415 (25.6) 755 (29.8) 0.003
0.56 78 (4.8) 98 (3.9) 0.14
0.09 311 (19.2) 507 (20.0) 0.51
0.91 206 (12.7) 316 (12.5) 0.83
0.001 277 (17.1) 487 (19.2) 0.08
0.10 268 (16.5) 441 (17.4) 0.46
0.61 163 (10.1) 280 (11.1) 0.31
0.08 147 (9.1) 202 (8.0) 0.22
0.002 227 (14.0) 392 (15.5) 0.19
–131.0) 0.20 128 (113.0–144.0) 128 (114.0–143.0) 0.99
0.33 1,073 (66.2) 1,572 (62.1) 0.007
0.87 1,039 (64.1) 1,676 (66.2) 0.17
0.90 332 (20.5) 489 (19.3) 0.36
0.001 1,361 (84.0) 2,107 (83.2) 0.53
0.11 112 (6.9) 171 (6.8) 0.85t Fai
olic Dy
eta-Bl
 1,2
(74.0–
(55.9)
13.5)
1.1)
79.2)
0.2)
3.2)
2.8)
3.2)
58.3)
41.7)
52.6)
36.1)
28.0)
33.6)
27.1)
3.2)
15.5)
14.5)
18.1)
17.3)
8.2)
11.2)
17.7)
106.0
63.4)
61.4)
19.1)
77.4)
4.3)
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Clinical Effectiveness of Beta-Blockers January 13, 2009:184–92In the preserved systolic function cohort (n  4,153),
hich included patients with heart failure and preserved
ystolic function who were eligible for beta-blockers and
aïve to beta-blockers at admission, 1,621 patients
39.0%) were discharged on beta-blocker therapy. Table
shows the baseline characteristics of the cohort by
ischarge beta-blocker status. Patients discharged on
eta-blockers were more often nonwhite and had a higher
requency of ischemic heart failure than patients dis-
harged without beta-blockers. Eligible patients dis-
harged without beta-blockers had higher median LVEF
nd higher prevalence of atrial arrhythmia and chronic
bstructive pulmonary disease.
Table 2 shows the discharge therapies for the 2 cohorts.
n general, patients discharged on beta-blocker therapy in
oth cohorts were more likely to be taking ACE inhibitors
r ARBs, antiplatelet agents, lipid-lowering agents, and
ldosterone antagonists. In-patient cardiac catheterization
ates were higher in both cohorts for patients discharged on
eta-blocker therapy.
Observed 1-year mortality for all patients who were
ligible for and naïve to beta-blockers at admission was
2.8%, and the 1-year all-cause rehospitalization rate was
4.3%. In the LVSD cohort, 1-year mortality was 34.3%
nd the 1-year rehospitalization rate was 63.2%. In the
reserved systolic function cohort, 1-year mortality was
1.7% and the rehospitalization rate was 65.0%. One-year
urvival for eligible patients initiated on beta-blocker ther-
py compared with eligible patients not initiated on beta-
locker therapy at discharge is shown in Figure 2 for
atients with LVSD and in Figure 3 for patients with
reserved systolic function.
In both cohorts, the discrimination of the propensity
odel was moderate, indicating that the treatment groups
ere similar enough to be adjusted using propensity weights
22). The c statistics for the propensity models were 0.67 in
he LVSD cohort and 0.63 in the preserved systolic dys-
ischarge Therapy and Procedures for Eligible Patients With Heart
Table 2 Discharge Therapy and Procedures for Eligible Patients
Left Ventricular Systolic Dysfunct
Variable
Beta-Blockers
(n  1,800)
No Beta-Blockers
(n  1,201)
Discharge medications
ACE inhibitor or ARB 1,383 (76.8) 747 (62.2)
Aldosterone antagonist 328 (18.2) 129 (10.7)
Antiplatelet 1,081 (60.1) 604 (50.3)
Digoxin 681 (37.8) 452 (37.6)
Diuretic 1,515 (84.2) 994 (82.8)
Lipid-lowering agent 635 (35.3) 364 (30.3)
In-hospital procedures
Coronary angiography 368 (20.4) 83 (6.9)
ICD placement 68 (3.8) 43 (3.6)
Mechanical ventilation 64 (3.6) 15 (1.2)
alues are expressed as n (%) unless otherwise indicated.
ACE  angiotensin-converting enzyme; ARB  angiotensin receptor blocker; ICD  implantableunction cohort. In both models, the most importantariables, defined as those with the highest Wald chi-square
alues, included other discharge therapies (i.e., antiplatelet
herapy, ACE inhibitor, or ARB) and within-hospital
ngiography. After observations were weighted by their
ropensity for treatment received, none of the factors listed
n Tables 1 or 2 differed significantly between treatment
roups in either cohort.
Table 3 shows the unadjusted and adjusted results for
ncident beta-blocker therapy at discharge compared with
o beta-blocker therapy for both cohorts. In the LVSD
ohort, we observed a protective effect of beta-blocker
herapy on mortality and on the combined end point of
ortality and rehospitalization. After adjustment, the haz-
rd rate for mortality was 23% lower for patients newly
No beta-blocker
Beta-blocker
Su
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Days From Discharge
Figure 2
1-Year Survival for Eligible Patients With
LVSD on Beta-Blocker Therapy Versus Patients
Not on Beta-Blocker Therapy at Discharge
Comparison of Kaplan-Meier survival curves at 1 year. The solid line repre-
sents eligible patients who were not on beta-blocker therapy at discharge. The
dashed line represents eligible patients who were on beta-blocker therapy at
discharge. LVSD  left ventricular systolic dysfunction.
re and Left Ventricular Systolic Dysfunction
h Heart Failure and Left Ventricular Systolic Dysfunction
Preserved Systolic Function
p Value
Beta-Blockers
(n  1,621)
No Beta-Blockers
(n  2,532) p Value
0.001 1,046 (64.5) 1,373 (54.2) 0.001
0.001 150 (9.3) 181 (7.1) 0.02
0.001 920 (56.8) 1,111 (43.9) 0.001
0.91 330 (20.4) 581 (22.9) 0.05
0.31 1,290 (79.6) 2,051 (81.0) 0.26
0.005 511 (31.5) 653 (25.8) 0.001
0.001 146 (9.0) 99 (3.9) 0.001
0.78 8 (0.5) 5 (0.2) 0.10
0.001 36 (2.2) 39 (1.5) 0.11
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ligible but not discharged on beta-blocker therapy. For the
ombined end point, the adjusted hazard rate was 13%
ower for patients newly initiated on beta-blocker therapy.
fter adjustment, incident beta-blocker therapy at discharge
id not have a statistically significant effect on the hazard of
ehospitalization among patients with LVSD. Among pa-
ients with preserved systolic function, incident beta-blocker
herapy at discharge did not have a statistically significant
ffect on mortality, rehospitalization, or the combined end
oint after adjustment.
In sensitivity analyses, we explored outcomes in sub-
roups of patients with LVSD, including patients with and
ithout chronic obstructive pulmonary disease, renal insuf-
ciency, and diabetes mellitus. Table 4 shows the relatively
omogeneous findings for mortality in these subgroups.
ased on   0.01 as a significant interaction, adjusted
azard ratios for beta-blocker therapy showed no significant
eterogeneity in patients with chronic obstructive pulmo-
ary disease, diabetes mellitus, and renal insufficiency and in
atients age 65 to 74 years and 75 years and older. The
ndings were similar for rehospitalization and the combined
nd point of mortality and rehospitalization in these sub-
roups. We performed subgroup analyses of patients with
reserved systolic function (Online Appendix). We also
xamined 937 patients with measured ejection fractions of
0% to 49%. In this group, 454 (48%) patients initiated
eta-blocker therapy at discharge. The unadjusted and
nverse-weighted hazard ratios for initiation of beta-blocker
herapy compared with no beta-blocker were similar. The
djusted hazard ratios were 0.95 (95% confidence interval
Figure 3
1-Year Survival for Eligible Patients With Preserved
Systolic Function on Beta-Blocker Therapy Versus
Patients Not on Beta-Blocker Therapy at Discharge
Comparison of Kaplan-Meier survival curves at 1 year. The solid line repre-
sents eligible patients who were not on beta-blocker therapy at discharge. The
dashed line represents eligible patients who were on beta-blocker therapy at
discharge.CI]: 0.75 to 1.20) for mortality, 0.91 (95% CI: 0.78 to.07) for rehospitalization, and 0.90 (95% CI: 0.78 to 1.04)
or mortality/rehospitalization.
iscussion
his study of clinical effectiveness addresses important
uestions about heart failure and beta-blockers by linking a
arge contemporary heart failure registry containing data on
linical characteristics, treatment eligibility, and contraindi-
ations and intolerance with long-term outcome data from
edicare claims. The registry includes a broad cohort of
atients (including elderly patients) with heart failure from
variety of settings and from all regions of the U.S. The
egistry contains far more detailed information on patient
haracteristics, presenting symptoms, treatments, and out-
omes than has been available in other administrative
atasets or registries. We confined the analysis to patients
ho were eligible for beta-blocker therapy and who did not
ave documented contraindications, intolerance, or other
easons for not receiving beta-blockers. We found that
eta-blockers were clinically effective in patients with
VSD, a population that is older and has more comorbid
onditions than populations usually enrolled in randomized
linical trials. Moreover, although patients with preserved
ystolic function had substantial morbidity and mortality
fter hospitalization for heart failure, in marked contrast to
atients with LVSD, we did not find a substantial benefit of
eta-blocker therapy in this cohort.
In comparison with clinical trials, in which the median
ge was 65 years (4–6,12), the median age in our study was
8 years, and the patients had significant comorbidities.
eta-blockers were prescribed at discharge for nearly 80% of
ll eligible patients with LVSD, a striking finding given the
revalence of comorbid conditions such as diabetes mellitus,
hronic obstructive pulmonary disease, renal insufficiency,
nd peripheral vascular disease, which are often perceived by
ractitioners as barriers to beta-blocker therapy. The overall
isk in this study population is further highlighted by the 1-year
ortality rate of 33%. In contrast, the COPERNICUS
Carvedilol Prospective Randomized Cumulative Survival)
rial, which enrolled patients with an LVEF 25%, had an
azard Ratios for Initiation of Beta-Blockerherapy Ver us No Beta-Blocker Therapy
Table 3 Hazard Ratios for Initiation of Beta-BlockerTherapy Versus No Beta-Blocker Therapy
Hazard Ratio
(95% Confidence Interval)
Population and Outcome Unadjusted Inverse-Weighted
Left ventricular systolic dysfunction
(n  3,001)
Mortality 0.65 (0.57–0.73) 0.77 (0.68–0.87)
Readmission 0.82 (0.75–0.90) 0.89 (0.80–0.99)
Combined 0.79 (0.72–0.86) 0.87 (0.79–0.96)
Preserved systolic dysfunction
(n  4,153)
Mortality 0.87 (0.77–0.97) 0.94 (0.84–1.07)
Readmission 0.96 (0.88–1.03) 0.98 (0.90–1.06)Combined 0.95 (0.88–1.02) 0.98 (0.91–1.06)
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onths (6). The observed 1-year mortality benefit in this
tudy is especially remarkable, given that eligible patients
ho were discharged without beta-blocker therapy may
ave subsequently started treatment and patients discharged
n beta-blockers may have discontinued therapy or been
onadherent.
Our findings also highlight the risks of decompensation
nd cardiovascular and noncardiovascular hospital admis-
ions among patients with heart failure. We found an
ll-cause rehospitalization rate of more than 60% in the first
ear. Previous clinical trials that included patients with
evere heart failure had rehospitalization rates of 30%
ensitivity Analyses of Subgroups in Patients With Heart Failure an
Table 4 Sensitivity Analyses of Subgroups in Patients With Hea
Subgroup
No. of
Events
Unadjusted Haza
(95% Confidence I
Mortality
Chronic obstructive pulmonary disease
No (n  2,224) 734 0.59 (0.51–0
Yes (n  777) 301 0.84 (0.67–1
Renal insufficiency
No (n  2,544) 806 0.68 (0.59–0
Yes (n  457) 229 0.59 (0.45–0
Diabetes mellitus
No (n  1,916) 629 0.63 (0.54–0
Yes (n  1,085) 406 0.68 (0.56–0
Age, yrs
65–74 (n  966) 231 0.67 (0.51–0
75 (n  2,035) 804 0.67 (0.59–0
All-cause readmission
Chronic obstructive pulmonary disease
No (n  2,224) 1,360 0.81 (0.73–0
Yes (n  777) 538 0.86 (0.73–1
Renal insufficiency
No (n  2,544) 1,563 0.83 (0.75–0
Yes (n  457) 335 0.79 (0.64–0
Diabetes mellitus
No (n  1,916) 1,145 0.84 (0.75–0
Yes (n  1,085) 753 0.78 (0.78–0
Age, yrs
65–74 (n  966) 608 0.73 (0.62–0
75 (n  2,035) 1,290 0.87 (0.78–0
Combined mortality and readmission
Chronic obstructive pulmonary disease
No (n  2,224) 1,573 0.77 (0.70–0
Yes (n  777) 613 0.86 (0.73–1
Renal insufficiency
No (n  2,544) 1,795 0.81 (0.74–0
Yes (n  457) 391 0.74 (0.61–0
Diabetes mellitus
No (n  1,916) 1,330 0.79 (0.71–0
Yes (n  1,085) 856 0.77 (0.67–0
Age, yrs
65–74 (n  966) 660 0.73 (0.62–0
75 (n  2,035) 1,526 0.83 (0.75–0
Hazard ratios are for 1-year outcomes of beta-blocker versus no beta-blocker at discharge.ithin 1 year (6). We found a significant reduction in the dombination of mortality and all-cause rehospitalization
ith beta-blocker therapy for patients with heart failure and
VSD, although the major effect was on mortality alone.
We also found that elderly patients with heart failure and
reserved systolic dysfunction had very high mortality and
orbidity, with a 1-year mortality rate of 32% and a 1-year
ehospitalization rate of 65%. Despite the alarming risk,
linical trial data regarding treatment for patients with heart
ailure and preserved systolic function are sparse. Beta-
lockers may be beneficial in patients with preserved systolic
unction who also have other indications, such as coronary
rtery disease, diabetes mellitus, or hypertension. However,
e found no association between beta-blocker therapy at
ft Ventricular Systolic Dysfunction
ilure and Left Ventricular Systolic Dysfunction
io
l)*
p Value for
Interaction
Inverse-Weighted Hazard Ratio
(95% Confidence Interval)*
p Value for
Interaction
0.008 0.02
0.69 (0.60–0.80)
1.00 (0.80–1.25)
0.31 0.22
0.79 (0.69–0.91)
0.66 (0.51–0.86)
0.57 0.94
0.77 (0.66–0.90)
0.76 (0.64–0.94)
0.96 0.87
0.76 (0.59–0.98)
0.78 (0.68–0.90)
0.52 0.69
0.89 (0.80–0.99)
0.92 (0.78–1.09)
0.69 0.76
0.89 (0.81–0.99)
0.86 (0.69–1.07)
0.45 0.40
0.92 (0.82-1.04)
0.84 (0.73-0.97)
0.07 0.13
0.80 (0.68–0.94)
0.94 (0.84–1.05)
0.23 0.23
0.84 (0.76–0.93)
0.95 (0.81–1.11)
0.43 0.37
0.88 (0.80–0.97)
0.79 (0.64–0.96)
0.74 0.63
0.88 (0.79–0.99)
0.84 (0.73–0.96)
0.16 0.24
0.80 (0.69–0.94)
0.90 (0.82–1.00)d Le
rt Fa
rd Rat
nterva
.68)
.06)
.78)
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.85)
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.89)
.90)
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.92)ischarge and clinical outcomes in the first year of follow-up
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January 13, 2009:184–92 Clinical Effectiveness of Beta-Blockersn patients admitted with preserved systolic function. There
re several possible explanations for the lack of benefit of
eta-blockers in this cohort, including the heterogeneity of
he population and poor understanding of pathophysiology.
he single randomized trial of beta-blockers that included
atients with preserved systolic function did not find a
ortality benefit in the subgroup of patients with LVEF of
t least 40% (23). Thus, our findings among patients
nrolled in the OPTIMIZE-HF registry are consistent with
he existing clinical trial evidence. More studies are needed
o address this high-risk population and to prospectively test
ew therapies that could improve outcomes.
Our study strengthens the findings of previous studies by
ncluding important clinical characteristics, such as LVEF,
nd prospective data on eligibility for treatment, including
ontraindications and intolerance. Go et al. (24) analyzed
edical records from 2 health care systems to assess the
omparative effectiveness of beta-blockers on the risk of
ehospitalization for heart failure. After adjustment for risks
f admission and propensity to receive beta-blockers, they
id not find significant differences in rehospitalization
ithin 12 months for patients on atenolol, metoprolol
artrate, carvedilol, or other beta-blockers. Because the
tudy had limited data on beta-blockers primarily studied
n clinical trials and did not have data on LVEF, the
mportance of evidence-based beta-blockers versus non–
vidence-based beta-blockers could not be determined. The
triking difference by left ventricular function in the associ-
tion of beta-blocker therapy with post-discharge outcomes
n our study highlights the importance of accurate docu-
entation of left ventricular function for studies of effec-
iveness in patients with heart failure. The difference also
akes it unlikely that observations of improved outcomes in
atients with LVSD were simply a result of lower-risk
atients being treated with beta-blockers or residual con-
ounding, because these would have applied equally to
atients with preserved systolic function.
tudy limitations. First, hospitals participating in the
PTIMIZE-HF registry were self-selected and may not be
epresentative of national care patterns and clinical out-
omes. Second, the follow-up data included were derived
rom the subset of patients in the registry who were enrolled
n fee-for-service Medicare. Third, eligibility for beta-
locker therapy is based on documentation in the medical
ecord and is thus dependent on the accuracy of this
ocumentation. Some patients may have had contraindica-
ions or intolerances that were not documented. Fourth, we
id not assess exposure to beta-blockers after hospital
ischarge, and patients discharged without beta-blocker
herapy may have started treatment and those discharged
ith beta-blocker therapy may have discontinued or not
ully adhered to therapy after discharge. A prior analysis of
he OPTIMIZE-HF registry showed that in a pre-specified
0% sample of patients with 60 to 90 days of follow-up,
5% of eligible patients discharged on beta-blocker therapy
emained on therapy (25). Any drop-off in beta-blockerherapy would diminish the likelihood of finding a signifi-
ant difference in post-discharge clinical outcomes, making
he findings of a significant difference in survival based on
ischarge use of beta-blocker therapy more remarkable.
lso, we did not assess health-related quality of life,
unctional capacity, patient satisfaction, or other outcomes
hat may be of interest; beta-blockers may or may not be
ssociated with these outcomes in clinical practice. Also, we
id not have data ascertaining causes of death and rehospi-
alization. Some studies have suggested that there are
ifferences in mode of death between heart failure patients
ith reduced and preserved systolic functions (26).
The association between beta-blocker therapy and out-
omes may be confounded by socioeconomic factors that are
ot included in the multivariable and propensity models.
here may also be other unmeasured confounders that, had
hey been adjusted for, would have strengthened or weak-
ned the association between beta-blocker use and clinical
utcomes. This study was observational, and randomized,
ontrolled trials are the best methods for establishing or
omparing efficacy of treatment. However, it is unlikely that
dditional randomized comparisons for beta-blockers either
roadly or in special populations, such as patients with
reserved systolic function, will be conducted. Thus, our
ata serve as one of the few resources for improving
nderstanding of clinical effectiveness in patients hospital-
zed for heart failure.
onclusions
n an elderly population hospitalized for heart failure,
ncident beta-blocker therapy at discharge was associated
ith significantly improved risk and propensity-adjusted
urvival for patients with LVSD in the first year of follow-
p. These findings extend the results of randomized clinical
rials of beta-blockers conducted in selected outpatients
ith chronic systolic heart failure to a diverse cohort of
atients hospitalized with heart failure and LVSD. Patients
ith heart failure and preserved systolic function have poor
utcomes, and beta-blockers do not substantially influence
he risk of death or rehospitalization in these patients.
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APPENDIX
or the supplementary tables on the results of a propensity model with
utcome of initiation of beta-blocker therapy at discharge in the left
entricular systolic dysfunction cohort and preserved systolic dysfunction
ohort, and a sensitivity analysis of subgroups in patients with heart failure
nd preserved systolic dysfunction, please see the online version of this
rticle.
